Compare Ascendis Pharma A/S (ASND) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Sprott Uranium Miners ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Sprott Uranium Miners ETF trades at $52.7. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| ASND | URNM | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $277.18 | $83.99 |
52-Week Low | $163.32 | $44.14 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
URNM trades at $53.29, up 2.07% today, but faces bearish technical signals with 15 sell indicators versus 4 buy signals. The uranium miner ETF benefits from AI-driven power demand, with Seeking Alpha highlighting a 'nuclear renaissance' thesis (June 12, 2026), though concentration in miners like Cameco poses risks. Financial ratios are unavailable, limiting fundamental clarity.
Outlook hinges on uranium supply-demand dynamics and AI energy needs, but technical weakness and mixed sentiment suggest cautious entry. Risks include miner concentration and spot price volatility, while institutional interest in nuclear energy offers long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
